Receptor activator of nuclear factor kappa-B ligand (RANKL) (RANKL)

Receptor activator of nuclear factor kappa-B ligand (RANKL) is a member of the tumor necrosis factor (TNF) cytokine family and serves as a critical regulator of bone remodeling and immune system function (UniProt: O14788). It is primarily produced by osteoblasts, bone marrow stromal cells, and activated T-cells, existing in both membrane-bound and soluble forms (NCBI Gene: 2919). RANKL exerts its primary biological effect by binding to its cognate receptor, RANK, located on the surface of osteoclast precursors and mature osteoclasts, which stimulates their differentiation, activation, and survival (StatPearls: NBK534833). This process is naturally balanced by osteoprotegerin (OPG), a decoy receptor that sequesters RANKL to prevent excessive bone loss. Dysregulation of the RANKL/RANK/OPG signaling pathway, particularly an excess of RANKL, is a central driver of pathological bone loss in conditions such as postmenopausal osteoporosis, rheumatoid arthritis, and bone metastases from solid tumors (PubMed: 15356477). Therapeutic targeting of RANKL, most notably with the fully human monoclonal antibody denosumab, effectively inhibits osteoclast-mediated bone resorption. By preventing the RANKL-RANK interaction, these therapies increase bone mineral density and significantly reduce the risk of skeletal-related events and fractures (DrugBank: DB06643). Beyond bone metabolism, RANKL also plays roles in lymph node organogenesis and mammary gland development during pregnancy (PubMed: 12748650).

Other names

TNFSF11Tumor necrosis factor ligand superfamily member 11TNF-related activation-induced cytokineTRANCEOsteoprotegerin ligandOPGLOsteoclast differentiation factorODFCD254

Denosumab is a human monoclonal antibody that binds to RANKL with high affinity, preventing it from activating its receptor, RANK, on the surface of osteoclasts and their precursors. This blockade inhibits the formation, function, and survival of osteoclasts, thereby reducing bone resorption and increasing bone mass in both cortical and trabecular bone (DrugBank: DB06643; StatPearls: NBK534833).